SMT202100350T1 - Pastiglia orodispersibile contenente etetrolo - Google Patents

Pastiglia orodispersibile contenente etetrolo

Info

Publication number
SMT202100350T1
SMT202100350T1 SM20210350T SMT202100350T SMT202100350T1 SM T202100350 T1 SMT202100350 T1 SM T202100350T1 SM 20210350 T SM20210350 T SM 20210350T SM T202100350 T SMT202100350 T SM T202100350T SM T202100350 T1 SMT202100350 T1 SM T202100350T1
Authority
SM
San Marino
Prior art keywords
tablet containing
orodispersible tablet
containing estetrol
estetrol
orodispersible
Prior art date
Application number
SM20210350T
Other languages
English (en)
Italian (it)
Inventor
Johannes Jan Platteeuw
Séverine Francine Isabelle Jaspart
Den Heuvel Denny Johan Marijn Van
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of SMT202100350T1 publication Critical patent/SMT202100350T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM20210350T 2015-06-18 2016-06-20 Pastiglia orodispersibile contenente etetrolo SMT202100350T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15172755 2015-06-18
EP16733352.5A EP3310346B1 (en) 2015-06-18 2016-06-20 Orodispersible tablet containing estetrol
PCT/EP2016/064181 WO2016203044A1 (en) 2015-06-18 2016-06-20 Orodispersible tablet containing estetrol

Publications (1)

Publication Number Publication Date
SMT202100350T1 true SMT202100350T1 (it) 2021-07-12

Family

ID=53476702

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210350T SMT202100350T1 (it) 2015-06-18 2016-06-20 Pastiglia orodispersibile contenente etetrolo

Country Status (19)

Country Link
US (1) US10888518B2 (enExample)
EP (1) EP3310346B1 (enExample)
JP (1) JP6813150B2 (enExample)
CN (1) CN107750157B (enExample)
CA (1) CA2988362C (enExample)
CY (1) CY1124052T1 (enExample)
DK (1) DK3310346T3 (enExample)
ES (1) ES2877476T3 (enExample)
HR (1) HRP20210555T1 (enExample)
HU (1) HUE054551T2 (enExample)
LT (1) LT3310346T (enExample)
MA (1) MA44206B1 (enExample)
MD (1) MD3310346T2 (enExample)
PL (1) PL3310346T3 (enExample)
PT (1) PT3310346T (enExample)
RS (1) RS61777B1 (enExample)
SI (1) SI3310346T1 (enExample)
SM (1) SMT202100350T1 (enExample)
WO (1) WO2016203044A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053274B2 (en) 2011-06-01 2021-07-06 Estetra S.P.R.L. Process for the production of estetrol intermediates
MX342537B (es) 2011-06-01 2016-10-04 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HRP20200850T1 (hr) 2015-06-18 2020-10-02 Estetra Sprl Orodisperzibilna jedinica za doziranje koja sadrži komponentu estetrola
EP3106148B1 (en) 2015-06-18 2018-03-14 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
JP6866561B2 (ja) * 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
GB2617040B (en) * 2019-09-27 2024-03-27 Ind Chimica Srl Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol)
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
MX2023003432A (es) * 2020-09-29 2023-08-04 Millicent Pharma Ltd Formulaciones orodispersables.
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
SK287095B6 (sk) 1999-12-02 2009-12-07 N.V. Organon Androgénové zlúčeniny, použitie androgénových zlúčenín a súprava s ich obsahom
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
CA2447178C (en) 2001-05-18 2010-06-08 Christian Franz Holinka Pharmaceutical composition for use in hormone replacement therapy
CA2448273C (en) 2001-05-23 2010-06-29 Christian Franz Holinka Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
PT1390042E (pt) 2001-05-23 2008-03-10 Pantarhei Bioscience Bv Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
EP1446128B1 (en) 2001-11-15 2006-12-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
ES2274107T3 (es) 2002-02-21 2007-05-16 Bayer Schering Pharma Ag Composiciones farmaceuticas comprendiendo uno o mas esterioides, uno o mas componentes de tetrahidrofolato vitamina b12.
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
ES2274252T3 (es) 2002-06-11 2007-05-16 Pantarhei Bioscience B.V. Metodo de tratamiento o prevencion de desordenes de medicion inmune y formulacion farmaceutica para su uso en ellos.
WO2003103685A1 (en) 2002-06-11 2003-12-18 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
PT1526856E (pt) 2002-07-12 2008-04-11 Pantarhei Bioscience Bv Composição farmacêutica que compreende derivados do estretol para ser utilizada no tratamento do cancro
PT1539184E (pt) 2002-08-28 2007-02-28 Robert Casper Regímen de substituição de estrogénio
AU2003274823A1 (en) 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
DK1558265T3 (da) 2002-11-05 2010-03-15 Bayer Schering Pharma Ag Anvendelse af dropspirenon til behandling af hypertension
PT1562976E (pt) 2002-11-08 2010-08-12 Pantarhei Bioscience Bv Síntese do estetrol via esteróides derivados da estrona
EP1624878B1 (en) 2003-05-22 2006-09-27 Pantarhei Bioscience B.V. Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain
JP4880465B2 (ja) 2003-09-29 2012-02-22 ノボ・ノルディスク・フェムケア・アーゲー 向上した安定性のプロゲストーゲン製剤
JP2007506796A (ja) 2003-09-29 2007-03-22 ノボ・ノルディスク・フェムケア・アーゲー Ｈｒｔ製剤
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
CN1557291A (zh) * 2004-01-14 2004-12-29 杨喜鸿 那格列奈分散片及其制备方法
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
SI1755562T1 (sl) 2004-05-28 2014-02-28 Richter Gedeon Nyrt. Kontracepcijsko sredstvo, ki vsebuje folno kislino
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
UA92348C2 (en) 2005-05-26 2010-10-25 Солвей Фармасьютикалс Гмбх 17b-HSD1 AND STS INHIBITORS
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
EP1971344B1 (en) 2006-01-09 2010-09-22 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
SG172654A1 (en) 2006-03-02 2011-07-28 Warner Chilcott Co Llc Extended cycle multiphasic oral contraceptive method
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
MX2008014941A (es) 2006-06-08 2008-12-10 Warner Chilcott Co Inc Metodos para administrar formas de dosificacion solida de etinil estradiol y profarmacos del mismo con biodisponibilidad mejorada.
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
KR20090029824A (ko) 2006-07-06 2009-03-23 바이엘 쉐링 파마 악티엔게젤샤프트 피임용 및 선천성 기형 위험 예방용 제약 제제
TW200831139A (en) 2006-11-29 2008-08-01 Wyeth Corp Estrogen/SERM and estrogen/progestin bi-layer tablets
WO2008079245A2 (en) 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
DE602008001783D1 (de) 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
AU2008206476A1 (en) 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
US8367647B2 (en) 2007-06-21 2013-02-05 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
CN101778635A (zh) * 2007-07-19 2010-07-14 潘塔希生物科学股份有限公司 妊娠高血压病变或胎儿生长迟缓的治疗或预防
JP5399749B2 (ja) * 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
US20110250274A1 (en) * 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
BRPI1011815A2 (pt) 2009-06-23 2016-03-29 Bayer Pharma AG "composição farmacêutica para a contracepção de emergência"
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
AU2011240102B2 (en) 2010-04-15 2015-07-23 Bayer Intellectual Property Gmbh Very low-dosed solid oral dosage forms for HRT
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
MX342537B (es) 2011-06-01 2016-10-04 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
US11053274B2 (en) 2011-06-01 2021-07-06 Estetra S.P.R.L. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US10179107B2 (en) * 2011-07-19 2019-01-15 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (DHEA)
HRP20170797T1 (hr) 2011-08-11 2017-08-11 Estetra S.P.R.L. Primjena estetrola kao hitnog kontraceptiva
CA2848785A1 (en) 2011-09-16 2013-03-21 Ferring B.V. A fast dissolving pharmaceutical composition
PL2764008T3 (pl) 2011-10-07 2017-04-28 Estetra S.P.R.L. Sposób wytwarzania estetrolu
EP2790688B1 (en) 2011-12-13 2019-11-20 Arstat, Inc. A multiphasic contraceptive regimen for an oral formulation of progestin and estrogen
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
JP6126456B2 (ja) 2013-05-17 2017-05-10 東和薬品株式会社 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
EP3943079A1 (en) 2013-05-21 2022-01-26 Predictive Therapeutics, LLC Therapeutic and method of use
WO2015040051A1 (en) 2013-09-18 2015-03-26 Crystal Pharma, S.A.U. Process for the preparation of estetrol
JP6447931B2 (ja) 2013-12-12 2019-01-09 ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． エステトロール成分を含有する口腔内崩壊固体単位剤形
WO2016023009A1 (en) 2014-08-07 2016-02-11 Wake Forest University Health Sciences Compositions and methods for clearing a biological sample
ES2957543T3 (es) 2014-09-29 2024-01-22 Univ California Composiciones y métodos para mantener la función cognitiva
US20180125860A1 (en) 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
JP6866561B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
HRP20200850T1 (hr) 2015-06-18 2020-10-02 Estetra Sprl Orodisperzibilna jedinica za doziranje koja sadrži komponentu estetrola
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
EP3106148B1 (en) 2015-06-18 2018-03-14 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
CA2989975C (en) 2015-06-23 2021-10-12 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
CN111683664A (zh) 2018-02-07 2020-09-18 埃斯特拉私人有限责任公司 具有降低的心血管作用的避孕组合物

Also Published As

Publication number Publication date
ES2877476T3 (es) 2021-11-16
JP2018517715A (ja) 2018-07-05
PL3310346T3 (pl) 2021-10-25
HRP20210555T1 (hr) 2021-05-14
HK1254649A1 (en) 2019-07-26
MD3310346T2 (ro) 2021-06-30
CY1124052T1 (el) 2022-05-27
LT3310346T (lt) 2021-06-10
EP3310346B1 (en) 2021-03-24
HUE054551T2 (hu) 2021-09-28
DK3310346T3 (da) 2021-05-25
CN107750157B (zh) 2021-07-13
MA44206A (fr) 2018-04-25
RS61777B1 (sr) 2021-06-30
US10888518B2 (en) 2021-01-12
CA2988362C (en) 2022-07-19
MA44206B1 (fr) 2021-04-30
CA2988362A1 (en) 2016-12-22
WO2016203044A1 (en) 2016-12-22
EP3310346A1 (en) 2018-04-25
JP6813150B2 (ja) 2021-01-13
SI3310346T1 (sl) 2021-07-30
CN107750157A (zh) 2018-03-02
US20180153801A1 (en) 2018-06-07
PT3310346T (pt) 2021-04-22

Similar Documents

Publication Publication Date Title
HUS2200027I1 (hu) Esztetrol komponenst tartalmazó, szájban diszpergálódó adagolási egység
PL3310346T3 (pl) Dyspergowalna w ustach tabletka zawierająca estetrol
PL3310345T3 (pl) Ulegająca rozpadowi w jamie ustnej tabletka zawierająca estetrol
IL256283B (en) A dosage unit soluble in the oral cavity containing estrol
IL254818A0 (en) Ribociclib tablet
SG10201914087UA (en) Tablet
IL269239A (en) A pharmaceutical combination containing fonsimod
IL257335A (en) A depdc1-derived peptide and a component containing it
GB201504820D0 (en) Retention time standard
IL250235A0 (en) A peptide derived from urlc10 and a component containing it
IL250215A0 (en) A peptide derived from cdca1 and a component containing it
GB201511252D0 (en) Tablet
GB201520155D0 (en) Device for substance delivery into miniature vessels